Carrick Therapeutics Announces $35 Million Investment from Pfizer
Funding supports advancement of samuraciclib, an oral CDK7 inhibitor, in combination with endocrine therapy for HR+, HER2- advanced breast cancer Adam Schayowitz, Ph.D., Vice President and Development Head, Breast Cancer, Colorectal…